Development and validation of a risk score for detecting non-alcoholic fatty liver disease

被引:0
|
作者
Jiang, Zhili [1 ]
Li, Xiang [1 ]
Yang, Duo [1 ]
Qu, Chao [1 ]
Yi, Jiayi [1 ]
Gao, Hai [1 ]
机构
[1] Capital Med Univ, Beijing Anzhen Hosp, Ctr Coronary Heart Dis, Beijing 100029, Peoples R China
关键词
NHANES; nonalcoholic fatty liver disease; noninvasive assessment; risk score; ABDOMINAL ADIPOSITY; DIAGNOSIS; PREDICTION; OBESITY; MODEL;
D O I
10.1097/MD.0000000000040417
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The development of an easy-to-use noninvasive model to screen nonalcoholic fatty liver disease (NAFLD) is warranted. This study aimed to develop and validate a simple noninvasive NAFLD risk score (NARS). We used the National Health and Nutrition Examination Survey 2017 to March 2020 cycle data. The sample size of derivation and validation cohort were 4056 and 2502, separately. The NAFLD was determined by FibroScan (R) measured controlled attenuation parameter scores of >285 dB/m in the absence of excessive alcohol use, steatogenic medications use, and viral hepatitis. The NARS was derived from a multivariable logistic regression model and variables were selected based on Boruta analysis. The performance of NARS was internally validated and compared with previous models using receiver-operating characteristics curve and C-statistics. The NARS was established using waist circumference, triglycerides, alanine aminotransferase, and fasting glucose, and the total score ranges from 0 to 8, with an increasing risk of NAFLD. NARS demonstrated ideal discrimination in the validation cohort, with C-statistics of 0.832 (95% confidence interval, 0.801-0.824), and was not inferior to any existing models. The optimal cutoff point for predicting NAFLD was obtained at 4 scores with a sensitivity of 82% and specificity of 69%. We reported the derivation and internal validation of a novel and easy-to-use risk score for detecting the presence of NAFLD. NARS demonstrated ideal discrimination performance and was practical in clinical practice for selecting individuals at higher risk of NAFLD for further examination or intervention.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Non-alcoholic fatty liver disease
    Tuyama, Ana C.
    Chang, Charissa Y.
    JOURNAL OF DIABETES, 2012, 4 (03) : 266 - 280
  • [32] Non-alcoholic fatty Liver disease
    Calderaro, Julien
    Zafrani, Elie Serge
    ANNALES DE PATHOLOGIE, 2010, 30 (06) : 413 - 420
  • [33] Non-alcoholic fatty liver disease
    Farrell, Geoffrey C.
    Wardell, Rebecca
    Teoh, Narci
    Chitturi, Shiv
    INTERNAL MEDICINE JOURNAL, 2019, 49 (05) : 681 - 683
  • [34] Non-alcoholic fatty liver disease
    Adams, LA
    Angulo, P
    LIVER DISEASES: ADVANCES IN TREATMENT AND PREVENTION: IN HONOUR OF HANS POPPER'S 100TH BIRTHDAY, 2004, 137 : 250 - 270
  • [35] Non-Alcoholic Fatty Liver Disease
    Engin, Atilla
    OBESITY AND LIPOTOXICITY, 2017, 960 : 443 - 467
  • [36] Non-alcoholic fatty liver disease
    Brent A. Neuschwander-Tetri
    BMC Medicine, 15
  • [37] Non-alcoholic fatty liver disease
    Alba, LM
    Lindor, K
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (08) : 977 - 986
  • [38] Non-alcoholic fatty liver disease
    Sattar, Naveed
    Forrest, Ewan
    Preiss, David
    BMJ-BRITISH MEDICAL JOURNAL, 2014, 349
  • [39] Non-alcoholic fatty liver disease
    Li, Wenhao
    Alazawi, William
    CLINICAL MEDICINE, 2020, 20 (05) : 509 - 512
  • [40] Development and validation study of a non-alcoholic fatty liver disease risk scoring model among adults in China
    Zhang, Qian
    Wong, Carlos K. H.
    Kung, Kenny
    Chan, Joseph C. Y.
    Sy, Barre T. W.
    Lam, Marcus
    Xu, Xiang Gui
    Yang, Meng Feng
    Yu, Yang
    Lin, Xiu Ping
    Lam, Cindy L. K.
    FAMILY PRACTICE, 2017, 34 (06) : 667 - 672